FrancophonIA/ELRC3.0 huggingface dataset:
English: In one safety study in Jersey cows, at overdose of 60 µg/kg, administered on three occasions (1.5x the highest recommended dose), abomasal ulcers were observed.
Maltese: Fi studju wieħed dwar is-sigurtà fil-baqar ta' Jersey, b'doża eċċessiva ta' 60 µg/kg, mogħtija fi tliet okkażjonijiet (darba u nofs l-ogħla doża rakkomandata), kienu osservati ulċeri abomażali.
English: 2.7 ml of solution for injection in a pre-filled polypropylene colourless syringe with siliconised chlorobutyl stopper and a stainless steel needle with needle guard.
Maltese: 2.7 ml ta' soluzzjoni għall-injezzjoni f'siringa mimlija għal-lest mingħajr kulur tal-polypropylene b'tapp tal-chlorobutyl silikonizzat u labra tal-azzar inossidabbli bi protezzjoni tal-labra.
English: The efficacy was tested together with normal management practice.
Maltese: L-effikaċja kienet ittestjata flimkien ma' prattika ta' ġestjoni normali.
English: Colony stimulating factors regulate the production and functional activities of immune cells.
Maltese: Il-fatturi ta' stimulazzjoni tal-kolonji jirregolaw il-produzzjoni u l-attivitajiet funzjonali taċ-ċelluli immuni.
English: In one safety study in Jersey cows the margin of safety of this product was 1.5x the highest recommended dose (an overdose of 60µg/kg was administered on three occasions).
Maltese: Fi studju wieħed dwar is-sigurtà fil-baqar ta' Jersey, il-marġni ta' sigurtà ta' dan il-prodott kienet 1.5 darbiet dik tal-ogħla doża rakkomandata (doża eċċessiva ta' 60 µg/kg ingħatat fi tliet okkażjonijiet).
English: No information is available with regards to a possible immune reaction towards the product or towards the endogenous molecule (bG-CSF) after repeated use of the product in cows.
Maltese: L-ebda informazzjoni mhija disponibbli fir-rigward ta' reazzjoni immuni possibbli għall-prodott jew għall-molekula endoġena (bG-CSF) wara użu ripetut tal-prodott fil-baqar.
English: Concurrent administration of substances which alter immune function (e.g. corticosteroids or non steroidal anti-inflammatory drugs) may reduce the efficacy of the product.
Maltese: L-għoti fl-istess ħin ta' sustanzi li jibdlu l-funzjoni immuni (eż. kortikosterojdi jew mediċini kontra linfjammazzjoni mhux sterojdi) jista' jnaqqas l-effikaċja tal-prodott.
English: As an aid in a herd management programme, to reduce the risk of clinical mastitis in periparturient dairy cows and heifers during the 30 days following calving.
Maltese: Bħala għajnuna fi programm ta' ġestjoni tal-merħla, biex jitnaqqas ir-riskju ta' mastite klinika f'baqar tal-ħalib qabel u wara li jwelldu u erieħ matul it-30 jum wara t-twelid.
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Imrestor 15 mg solution for injection for cattle pegbovigrastim
Maltese: VETERINARJU Imrestor 15 mg soluzzjoni għal injezzjoni għall-ifrat pegbovigrastim
English: During the clinical field studies, non typical anaphylactoid type reactions were uncommonly observed.
Maltese: Fl-istudji kliniċi, kienu osservati reazzjonijiet anafilattiċi mhux tipiċi b'mod mhux komuni.
English: STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) The product is a clear, colourless to pale yellow solution for injection containing 15 mg pegbovigrastim (pegylated bovine colony stimulating factor) in a pre-filled syringe.
Maltese: Evidenza minn sustanzi attivi simili fil-bnedmin tissuġġerixxi li l-għoti aċċidentali lill-ifrat ta' aktar mid-doża awtorizzata jista' jirriżulta f'reazzjonijiet avversi, li huma relatati mal-attività ta' pegbovigrastim.
English: Disposal: read package leaflet
Maltese: MHUX APPLIK ABBLI
English: There is no information available about the pharmacokinetics of pegbovigrastim in cattle.
Maltese: M'hemm ebda informazzjoni diosponibbli dwar il-farmakokinetika ta' pegbovigrastim fl-ifrat.
English: 6.1 List of excipients
Maltese: 6.1 Lista ta' ingredjenti Monoidrat tal-aċidu ċitriku.
English: Evidence from similar active substances in humans suggests that accidental administration to cattle of more than the authorised dose could result in adverse reactions, which are related to the activity of pegbovigrastim.
Maltese: Evidenza minn sustanzi attivi simili fil-bnedmin tissuġġerixxi li l-għoti aċċidentali ta' aktar mid-doża awtorizzata jista' jirriżulta f'reazzjonijiet avversi, li huma relatati mal-attività ta' pegbovigrastim.
English: Bovine No MRL required
Maltese: L-ebda MRL
English: Cattle (dairy cows and heifers).
Maltese: kura waħda)
English: As expected from the mode of action of the active substance, safety data shows that a mild and transient rise in somatic cell counts in individual cows may be seen.
Maltese: Kif mistenni mill-mod ta' azzjoni tas-sustanza attiva, id-dejta dwar is-sigurtà turi li tista' tiġi osservata żieda ħafifa u temporanja fl-għadd ta' ċelloli somatiċi f'baqar individwali.
English: CONTRAINDICATIONS Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Maltese: KONTRAINDIKAZZJONIJIET Tużax f'każijiet ta' sensittività għall-ingredjent attiv jew ingredjenti oħra.
English: 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Maltese: .6 Prekawzjonijiet speċjali għar-rimi tal-prodotti mediċinali veterinarji mhux użata jew materjal ieħor għar-rimi li huwa derivat minn dawn il-prodotti
English: Further information on Revinty Ellipta can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Vilanterol is a long-acting beta-2 agonist.
Maltese: Vilanterol huwa agonista beta-2 li jaġixxi fit-tul.
English: Relvar Ellipta is available as an inhaler in two strengths (92/22 micrograms and 184/22 micrograms).
Maltese: Revinty Ellipta jiġi bħala inalatur f'żewġ qawwiet (92/22 mikrogramma u 184/22 mikrogramma).
English: Revinty Ellipta is an inhaler for treating asthma and chronic obstructive pulmonary disease (COPD).
Maltese: Revinty Ellipta huwa inalatur biex jikkura l-ażma u mard pulmonari ostruttiv kroniku (COPD, chronic obstructive pulmonary disease).
English: Other information about Revinty Ellipta
Maltese: Informazzjoni oħra dwar Revinty Ellipta
English: Revinty Ellipta received a marketing authorisation valid throughout the EU on 2 May 2014.
Maltese: Revinty Ellipta rċieva awtorizzazzjoni għat-tqegħid fis-suq valida fl-EU fit-2 ta' Mejju 2014.
English: Revinty Ellipta 184/22 also improved FEV1 by 193 ml more than fluticasone furoate and 210 ml more than another inhaler containing fluticasone propionate.
Maltese: Revinty Ellipta 184/22 tejjeb ukoll il-FEV1 b'193 ml aktar minn fluticasone furoate u b'210 ml aktar minn inalatur ieħor li fih fluticasone propionate.
English: Revinty Ellipta contains the active substances fluticasone furoate and vilanterol.
Maltese: Revinty Ellipta fih is-sustanzi attivi fluticasone furoate u vilanterol.
English: The first study showed that Revinty Ellipta 92/22 improved average FEV1 by 115 ml more than placebo, and a second study showed that Revinty Ellipta 184/22 improved average FEV1 by 131 ml more than placebo.
Maltese: L-ewwel studju wera li Revinty Ellipta 92/22 tejjeb il-FEV1 medju b'115 ml aktar mill-plaċebo, u t-tieni studju wera li Revinty Ellipta 184/22 tejjeb il-FEV1 medju b'131 ml aktar mill-plaċebo.
English: A fourth study in 1,522 patients showed that Revinty Ellipta was as effective as another medicine containing a corticosteroid (fluticasone propionate) and a long-acting beta-2 agonist (salmeterol).
Maltese: Ir-raba' studju f'1,522 pazjent wera li Revinty Ellipta kien effettiv daqs mediċina oħra li fiha kortikosterojde (fluticasone propionate) u agonista beta-2 li jaġixxi fit-tul (salmeterol).
English: In two further studies, Revinty Ellipta reduced the number of flare-ups by between 13 and 34% more than vilanterol alone
Maltese: F'żewġ studji oħra, Revinty Ellipta naqqas in-numru ta' episodji ta' feġġ mill-ġdid b'bejn 13 u 34 % aktar minn vilanterol waħdu.
English: How is Revinty Ellipta used?
Maltese: Kif jaħdem Revinty Ellipta?
English: Four studies in over 5,500 patients showed that Revinty Ellipta improves breathing and reduces flare ups of symptoms in patients with COPD.
Maltese: Erba' studji f'aktar minn 5,500 pazjent urew li Revinty Ellipta jtejjeb it-teħid tan-nifs u jnaqqas il-feġġ mill-ġdid tas-sintomi f'pazjenti bis-COPD.
English: What are the risks associated with Revinty Ellipta?
Maltese: X'inhuma r-riskji assoċjati ma' Revinty Ellipta?
English: In two of the studies, Revinty Ellipta 92/22 increased the volume of air a patient could breathe out in one second (FEV1) by 36 ml more than fluticasone furoate alone and 172 ml more than placebo (a dummy treatment).
Maltese: Fi tnejn mill-istudji, Revinty Ellipta 92/22 żied il-volum tal-arja li pazjent seta' joħroġ man-nifs f'sekonda (FEV1) b'36 ml aktar minn fluticasone furoate waħdu u b'172 ml aktar mill-plaċebo (kura finta).
English: As for all medicines, data on the use of Revinty Ellipta are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Revinty Ellipta hija ssorveljata kontinwament.
English: The company that makes Relvar Ellipta has agreed that its scientific data can be used for Revinty Ellipta (‘informed consent').
Maltese: Il-kumpanija li tipproduċi Relvar Ellipta qablet li d-data xjentifika tagħha tista' tintuża għal Revinty Ellipta (“kunsens infurmat”).
English: This medicine is the same as Relvar Ellipta, which is already authorised in the EU.
Maltese: Din il-mediċina hija l-istess bħal Relvar Ellipta, li diġà hija awtorizzata fl-UE.
English: How does Revinty Ellipta work?
Maltese: Kif jintuża Revinty Ellipta?
English: In a third study, fewer patients taking Revinty Ellipta 92/22 had at least one severe flare-up after a year of treatment than those taking fluticasone furoate alone (13% versus 16%).
Maltese: Fit-tielet studju, inqas pazjenti li kienu qed jieħdu Revinty Ellipta 92/22 kellhom tal-inqas feġġ mill-ġdid sever wieħed wara sena ta' kura minn dawk li kienu qed jieħdu fluticasone furoate waħdu (13% kontra
English: For the full list of side effects of Revinty Ellipta, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji ta' Revinty Ellipta, ara l-fuljett ta' tagħrif.
English: These patients were already well controlled with the comparator medicine and Revinty Ellipta treatment was able to maintain their FEV1.
Maltese: Dawn ilpazjenti diġà kienu kkontrollati tajjeb bil-mediċina komparatur u l-kura b'Revinty Ellipta setgħet iżżomm il-FEV1 tagħhom.
English: Regarding its safety, the most frequent side effects reported with Revinty Ellipta were similar to those seen with other COPD and asthma treatments; an increased incidence of pneumonia was observed in patients with COPD.
Maltese: Fir-rigward tas-sigurtà tiegħu, l-effetti sekondarji rrappurtati l-aktar ta' spiss b'Revinty Ellipta kienu simili għal dawk li dehru b'kuri oħrajn għas-COPD u għall-ażma; ġiet osservata żieda fl-inċidenza ta' pulmonite f'pazjenti bis-COPD.
English: The full EPAR and risk management plan summary for Voriconazole Hikma can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: L-EPAR sħiħ u s-sommarju tal-pjan tal-ġestjoni tar-riskju għal Voriconazole Hikma jinstabu fis-sit elettroniku tal-Aġenzija: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: • invasive aspergillosis (a type of fungal infection due to Aspergillus);
Maltese: • asperġillożi invażiva (tip ta' infezzjoni fungali kkawżata minn Aspergillus);
English: The active substance in Voriconazole Hikma, voriconazole, belongs to the ‘triazole' class of antifungal medicines.
Maltese: Is-sustanza attiva f'Voriconazole Hikma, il-vorikonażol, tagħmel parti mill-klassi "triażol” ta' mediċini antifungali.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Voriconazole Hikma on 27 May 2015.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Voriconazole Hikma fis-27 ta' Mejju 2015.
English: • other serious invasive Candida infections when the fungus is resistant to fluconazole (another antifungal medicine);
Maltese: • infezzjonijiet invażivi serji minn Candida meta l-fungu jkun reżistenti għal flukonażol (mediċina antifungali oħra);
English: Voriconazole Hikma voriconazole
Maltese: Voriconazole Hikma vorikonażol
English: • serious fungal infections caused by Scedosporium or Fusarium (two different types of fungus).
Maltese: • infezzjonijiet fungali serji kkawżati minn Scedosporium jew minn Fusarium (żewġ tipi differenti ta' fungu).
English: This is a summary of the European public assessment report (EPAR) for Voriconazole Hikma.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Voriconazole Hikma.
English: Because Voriconazole Hikma is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Billi Voriconazole Hikma huwa mediċina ġenerika, il-benefiċċju u r-riskji tiegħu jitqiesu l-istess bħal dawk tal-mediċina ta' referenza.
English: The list of fungi against which Voriconazole Hikma is active can be found in the summary of product characteristics (also part of the EPAR).
Maltese: Il-lista ta' fungi li Voriconazole Hikma huwa attiv kontrihom tinsab fis-sommarju tal-karatteristiċi tal-prodott (parti wkoll mill-EPAR).
English: Voriconazole Hikma is an antifungal medicine used for the treatment of adults and children over the age of two years who have the following infections caused by a fungus:
Maltese: Voriconazole Hikma huwa mediċina antifungali li tintuża għall-kura ta' adulti u tfal li għandhom aktar minn sentejn li għandhom l-infezzjonijiet li ġejjin ikkawżati minn fungu:
English: This means that Voriconazole Hikma is similar to a ‘reference medicine' already authorised in the European Union
Maltese: Dan ifisser li Voriconazole Hikma huwa simili għall-‘mediċina ta' referenza' diġà awtorizzata fl-Unjoni Ewropea (UE) bl-isem kummerċjali Vfend.
English: • candidaemia (a type of fungal infection due to Candida) in patients with a normal white blood cell count;
Maltese: • kandidemija (tip ieħor ta' infezzjoni fungali kkawżata minn Candida) f'pazjenti li għandhom għadd normali ta' ċelloli bojod fid-demm;
English: It works by disrupting the formation of ergosterol, which is an important part of fungal cell membranes.
Maltese: Din taħdem billi tipprevjeni l-formazzjoni tal-ergosterolu, li huwa parti importanti mill-ħitan taċ-ċelloli fungali.
English: Voriconazole Hikma contains the active substance voriconazole.
Maltese: Voriconazole Hikma fih is-sustanza attiva vorikonażol.
English: The Committee recommended that Voriconazole Hikma be approved for use in the EU.
Maltese: IlKumitat irrakkomanda li Voriconazole Hikma jkun approvat għall-użu fl-UE.
English: Why is Voriconazole Hikma approved?
Maltese: Għaliex ġie approvat Voriconazole Hikma?
English: Voriconazole Hikma is available as a powder to be made up into a solution for infusion (drip) into a vein.
Maltese: Voriconazole Hikma huwa disponibbli bħala trab sabiex ikun magħmul soluzzjoni għal infużjoni (dripp) fil-vina.
English: Voriconazole Hikma is also used to prevent fungal infections in patients who have had haematopoietic (blood) stem-cell transplantation (a transplant of a type of stem cells that can develop into blood cells) and are at high risk of infection.
Maltese: Voriconazole Hikma jintuża wkoll biex jipprevjeni infezzjonijiet fungali f'pazjenti li jkun sarilhom trapjant ta' ċelloli staminali (tad-demm) ematopojetiċi (trapjant ta' tip ta' ċelloli staminali li jistgħu jiżviluppaw f'ċelloli tad-demm) u li jkunu f'riskju għoli ta' infezzjoni.
English: There was no need for ‘bioequivalence' studies to investigate whether voriconazole is absorbed similarly to the reference medicine, Vfend, to produce the same level of the active substance in the blood.
Maltese: Ma kienx hemm bżonn għal studji ta' 'bijoekwivalenza' biex jinvestigaw jekk vorikonażol huwiex assorbit similarment bħall-mediċina ta' referenza, Vfend, biex jipproduċi l-istess livell ta' sustanza attiva fid-demm.
English: How has Voriconazole Hikma been studied?
Maltese: Kif ġie studjat Voriconazole Hikma?
English: How is Voriconazole Hikma used?
Maltese: Kif jaħdem Voriconazole Hikma?
English: Pharmathen International S.A Industrial Park Sapes Rodopi Prefecture, Block No 5 Rodopi 69300
Maltese: Pharmathen International S.A Industrial Park Sapes Rodopi Prefecture, Block No 5
English: Date of first authorisation: 16.10.2009 Date of latest renewal: 18.09.2014
Maltese: Data tal-ewwel awtorizzazzjoni: 16.10.2009 Data tal-aħħar tiġdid: 18.09.2014
English: Apotex Polska Sp. z o.o.
Maltese: Apotex Polska Sp. z o.o. Polsce
English: Pharmathen S.A., 6 Dervenakion 15351 Pallini Attiki Greece
Maltese: Pharmathen S.A., 6 Dervenakion 15351 Pallini Attiki
English: Pharmathen S.A. 6, Dervenakion 15351 Pallini Attiki Greece
Maltese: Pharmathen S.A. 6, Dervenakion 15351 Pallini Attiki
English: Microcrystalline cellulose Stearic acid
Maltese: Microcrystalline cellulose Aċidu steariku
English: Clopidogrel and the main circulating (inactive) metabolite bind reversibly in vitro to human plasma proteins (98% and 94% respectively).
Maltese: Clopidogrel u l-metabolita prinċipali (inattiv)ċirkolanti jintrabtu b'mod reversibbli in vitro mal- proteini umani tal-plażma (98% u 94% rispettivament).
English: Hypromellose (E464) Lactose monohydrate Triacetin (E1518) Titanium dioxide (E171) Red iron oxide (E172)
Maltese: Hypromellose (E464) Lattożju monoidrat Triacetin (E1518) Dijossidu tat-titanju (E171) Iron oxide aħmar (E172)
English: • Severe hepatic impairment.
Maltese: • Indeboliment epatiku gravi.
English: TROPICAL-ACS (Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes)
Maltese: TROPICAL-ACS (Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes - Provi ta' Rispons għal Impediment ta' Plejtlits fi Trattament Kroniku ta' Antiplejtlits f'Sindromi Koronarji Akuti )
English: Reproductive systems and breast disorders
Maltese: Disturbi tas-sistemi riproduttiva u ssider
English: TOPIC (Timing Of Platelet Inhibition after acute Coronary syndrome)
Maltese: TOPIC (Timing Of Platelet Inhibition after acute coronary syndrome - Iż-żmien ta' impediment bilplejtlits wara Sindrome Koronarju Akut)
English: Thrombocytopenia, leucopenia, eosinophilia
Maltese: Tromboċitopenija, lewkopenija, eosinofilija
English: anti-retroviral medicines (medicines to treat HIV infections).
Maltese: - mediċini antiretrovirali (mediċini għall-kura ta' infezzjonijiet bl-HIV).
English: 7 film-coated tablets 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 50 film-coated tablets 56 film-coated tablets 84 film-coated tablets 90 film-coated tablets 100 film-coated tablets
Maltese: 7-il pillola miksija b'rita 14 pillola miksija b'rita 28 pillola miksija b'rita 30 pillola miksija b'rita 50 pillola miksija b'rita 56 pillola miksija b'rita 84 pillola miksija b'rita 90 pillola miksija b'rita 100 pillola miksija b'rita
English: They are supplied in PVC/PE/PVDC/Alu blisters or in PA/ALL/PVC-Alu blisters packed in cartons containing 7, 14, 28, 30, 50, 56, 84, 90 or 100 film-coated tablets.
Maltese: Huma fornuti fi folji tal-PVC/PE/PVDC/Alu jew PA/ALL/PVC-Alu ppakkjati f'kartuni li fihom 7, 14, 28, 30, 50, 56, 84, 90 jew 100 pillola miksija b'rita.
English: Packs of 7, 14, 28, 30, 50, 56, 84, 90 or 100 film-coated tablets.
Maltese: Pakketti ta' 7, 14, 28, 30, 50, 56, 84, 90 jew 100 pillola miksija b'rita.
English: Medicinal products that are strong or moderate CYP2C19 inhibitors include for example omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, carbamazepine, and efavirenz.
Maltese: Prodotti mediċinali li huma inibituri qawwijin jew moderati ta' CYP2C19 jinkludu, per eżempju, omeprazole u esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine u efavirenz.
English: Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, eosinophilic pneumonia
Maltese: Fsada fil-passaġġ respiratorju (emottiżi, emorraġija filpulmun), bronkospażmu, pulmonite interstizjali, pulmonite eosinofilika
English: Their frequency is defined using the following conventions: common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Maltese: Il-frekwenza tagħhom hija definita skont dawn il-konvenzjonijiet: komuni (1/100 sa <1/10); mhux komuni (/1,000 sa <1/100); rari (1/10,000 sa <1/1,000); rari ħafna (<1/10,000), mhux magħruf (ma tistax tittieħed stima mid-data disponibbli).
English: The other ingredients are (see section 2 ‘Clopidogrel Apotex contains lactose'): Tablet core: hydroxypropylcellulose (E463), mannitol (E421), crospovidone (type A), citric acid monohydrate, microcrystalline cellulose, macrogol 6000, stearic acid, talc Tablet coating: lactose monohydrate (milk sugar), hypromellose (E464), triacetin (E1518), red iron oxide (E172) and titanium dioxide (E171),
Maltese: Qalba tal-pillola: idrossipropilċelluloża (E463), mannitol (E421), crospovidone (type A), aċidu ċitriku monoidrat, ċelluloża mikrokristallina, macrogol 6000, aċidu steariku, talc Rita tal-pillola: lactose monohydrate (iz-zokkor li jinsab fil-ħalib), hypromellose (E464), triacetin (E1518), iron oxide aħmar (E172) u titanium dioxide (E171),
English: Clopidogrel Apotex contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products.
Maltese: Clopidogrel Apotex fih clopidogrel u jifforma parti minn grupp ta' mediċini msejħa prodotti mediċinali ta' kontra l-plejtlets.
English: De-escalation of P2Y12 Inhibitor Agents in ACS
Maltese: Deskalazzjoni ta' Aġenti Impedituri ta' P2Y12 f'ACS
English: Respiratory, thoracic and mediastinal disorders
Maltese: Disturbi respiratorji, toraċiċi u mediastiniċi
English: The patient population included 19.7% women and 29.2% patients ≥ 65 years.
Maltese: Ilgrupp ta' pazjenti studjati kien jinkludi 19.7% nisa u 29.2% pazjenti ≥65 sena.
English: Gyanecomastia
Maltese: Gijanekomastija
English: The ACTIVE-A study (N=7,554) was a multicenter, randomized, double-blind, placebo-controlled study which compared clopidogrel 75 mg/day + ASA (N=3,772) to placebo + ASA (N=3,782).
Maltese: L-istudju ACTIVE-A (N=7,554), kien wieħed ikkontrollat bil-plaċebo, magħmul f'postijiet varji,doubleblind u randomized u li qabbel clopidogrel 75 mg/jum + ASA (N=3,772) ma' plaċebo + ASA (N=3,782).
English: Core:
Maltese: Qalba:
English: The active metabolite is formed mostly by CYP2C19 with contributions from several other CYP enzymes, including CYP1A2 CYP2B6 and CYP3A4.
Maltese: Il-metabolit attiv isir primarjament minn CYP2C19 b'kontribuzzjonijiet minn bosta enzimi CYP oħra li jinkludu CYP1A2, CYP2B6 u CYP3A4.
English: 2333 CN, Leiden The Netherlands
Maltese: 2333 CN, Leiden
English: There have been a number of retrospective analyses, however, to evaluate this effect in patients treated with clopidogrel for whom there are genotyping results: CURE (n=2721), CHARISMA (n=2428), CLARITY-TIMI 28 (n=227), TRITON-TIMI 38 (n=1477), and ACTIVE-A (n=601), as well as a number of published cohort studies.
Maltese: CURE (n=2,721), CHARISMA (n=2,428), CLARITY-TIMI 28 (n=227), TRITON-TIMI 38 (n=1,477), u ACTIVE-A (n=601), kif ukoll numru ta' studji ko-orti ppubblikati.
English: Store below 25°C (for PVC/PE/PVDC/aluminium blisters)
Maltese: Aħżen f'temperatura taħt 25°C (għall-folji tal-PVC/PE/PVDC/Aluminju)
English: The population included 27.8% women, 58.4% patients ≥ 60 years (26% ≥ 70 years) and 54.5% patients who received fibrinolytics.
Maltese: Il-grupp studjat inkluda 27.8% nisa, 58.4% pazjenti ≥60 sena (26% ≥70 sena) u 54.5% tal-pazjenti li rċevew is-sustanzi fibrinolitiċi.